Genmab — Januar 2017
-
nivolumab in combination with ipilimumab, BMS-986016 or daratumumab in human subjects who have the following types of tumors: Epstein Barr Virus (EBV) positive gastric cancer; EBV positive nasopharyngeal cancer (NPC); Human Papilloma Virus (HPV) positive cervical, vaginal, vulvar cancer; Other HPV-associated tumors (anal canal, penile), HPV positive squamous cell cancer of the head and neck (SCCHN); and Polyomavirus positive merkel cell cancer
-
BMS; A Study to Investigate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358) https://clinicaltrials.gov/ct2/show/NCT02488759?term=daratumumab&rank=37
-
Interessant - https://twitter.com/clahjoh/status/825485297261694976
-
God morgen.
-
God morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind